Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TSA-CTL in Advanced Solid Tumors
NCT02959905Phase 1Completed
- Sponsor
- BGI
- Start
- Dec 2016
- Primary completion
- Sep 2020
- Modality
- TCR-Engineered T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of TSA-CTL in solid tumor (3 arms), sponsored by BGI. Primary endpoint: Adverse Events at 1 month. Started Dec 2016; status: completed.
02
Drugs
TSA-CTL
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT02959905.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02959905.